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ABSTRACT
Introduction: Chronic obstructive pulmonary disease
(COPD) is associated with exercise limitation and
physical inactivity, which are believed to have
significant long-term negative health consequences
for patients. While a number of COPD treatments and
exercise training programmes increase exercise
capacity, there is limited evidence for their effects on
physical activity levels, with no clear association
between exercise capacity and physical activity in
clinical trials. Physical activity depends on a number
of behaviour, environmental and physiological factors.
We describe the design of the PHYSACTO trial, which
is investigating the effects of bronchodilators, either
alone or with exercise training, in combination with a
standardised behaviour-change self-management
programme, on exercise capacity and physical activity
in patients with COPD. It is hypothesised that
bronchodilators in conjunction with a behaviour-
change self-management programme will improve
physical activity and that this effect will be amplified
by the addition of exercise training.
Methods and analysis: Patients are being recruited
from 34 sites in Australia, New Zealand, the USA,
Canada and Europe. Patients receiving a
multicomponent intervention designed to support
behaviour change related to physical activity are
randomised to four treatment arms: placebo,
tiotropium, tiotropium+olodaterol, and tiotropium
+olodaterol+exercise training. The primary outcome is
improvement in exercise capacity after 8 weeks,
measured by endurance time during a shuttle walk
test. The secondary outcome is improvement in
physical activity, including objective accelerometer
assessment and patient-reported functioning using
the Functional Performance Inventory—Short Form
and the novel hybrid PROactive instrument.
Additionally, the influence of moderating variables (ie,
factors influencing a patient’s choice to be physically
active) on increases in physical activity is also
explored.
Ethics and dissemination: The study has been
approved by the relevant Institutional Review Boards,
Independent Ethics Committee and Competent
Authority according to national and international
regulations. The findings of the trial will be
disseminated through relevant peer-reviewed journals
and international conference presentations.
Trial registration number: NCT02085161.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is associated with low levels of phys-
ical activity in daily life, starting early in the
Strengths and limitations of this study
▪ One strength of this study is that we are
investigating the impact of a multimodal inter-
vention (pharmacotherapy, exercise training and
behaviour programme) on exercise capacity and
physical activity.
▪ Another strength is the use of a behaviour
change intervention combined with bronchodila-
tors and exercise training in a multicentre, multi-
national study to encourage physical activity.
▪ We also measure physical activity using both
accelerometers and patient-reported measures.
▪ A potential limitation to this work is that the
study is only partially double-blinded as it is not
possible to implement blinding in the exercise
training intervention; this will be taken into
account when data are analysed.
▪ A further limitation is that there is no control
group that is not receiving the behaviour change
intervention, so the effects of the behaviour
change intervention alone cannot be singled out.
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course of the disease.1 As breathlessness during activity
worsens, patients may avoid physical activity, thereby
causing muscle deconditioning and decreased exercise
capacity, which further encourage a sedentary
lifestyle.2 3
Higher levels of physical activity in patients with
COPD are associated with fewer symptoms, better
health-related quality of life and a lower frequency of
hospitalisations, exacerbations and mortality.4–7 In add-
ition, it is suggested that there is an inverse relationship
between activity level and rate of lung function
decline.3 8 However, it is difficult to establish a causal
relationship with these outcomes: as disease severity
increases, physical activity is likely to decrease.9
Improving exercise capacity and increasing physical
activity levels are different yet related goals in COPD
therapy.10 Exercise capacity is the amount of exercise
patients are physically capable of doing, while physical
activity reflects the amount of activity and the difficulty
patients have in their activities in daily life. The
European Respiratory Society statement on physical
activity highlights the need for further research into
physical activity in COPD.3
Exercise capacity can be directly measured in the
clinic. A number of drugs that improve airflow have
been shown to increase exercise capacity in COPD,
though effect sizes vary between trials.11–15 Various types
of exercise training also increase exercise capacity.16–20
One mechanism through which exercise training
improves exercise capacity is by improving skeletal
muscle function;21 22 this occurs when training intensity
is high enough to provide an overload stimulus on the
skeletal muscle.23 The combination of pulmonary
rehabilitation with bronchodilator therapy increases
exercise capacity to a greater extent than either compo-
nent alone,24 and guidelines recommend that optimal
bronchodilator therapy should be given prior to exercise
training to enhance performance in and outside the
training programme.25
A clear association in clinical trials between exercise
capacity and physical activity levels has yet to be shown,26
with little and conflicting evidence from randomised
controlled interventional studies demonstrating improve-
ments in physical activity with pharmacological treat-
ments (table 1) (range 4–11% increase).7 13 27–29 In the
PHYSACTO trial, it is assumed that improvement of
exercise capacity is a prerequisite for increasing physical
activity levels for the included interventions (broncho-
dilator therapy and exercise training) and, for this
reason, exercise capacity is the primary end point of the
study. It is becoming ever more apparent that increasing
physical activity necessitates a change in patient behav-
iour. Consistent with this, activity counselling with direct
feedback methods has been shown to improve physical
activity levels in patients with COPD,30–33 as long as the
intervention was maintained.34 The importance of be-
haviour change is reflected in the PHYSACTO trial by
the inclusion of a standardised behaviour-change pro-
gramme that is implemented in all treatment arms. This
is described in the parallel publication by Bourbeau
et al.35
It is also important to understand the experience of
physical activity from the patient’s perspective. The
Functional Performance Inventory—Short Form (FPI-SF) is
used to capture patient report of the extent and difficulty
with which patients perform daily activities, including those
related to personal care, family and social aspects of life
that people with COPD consider important.36 37 In add-
ition, a new approach to integrating quantity and quality of
physical activity has been developed using a patient-
derived concept,38 through the European Innovative
Medicines Initiative project, PROactive (http://www.
proactivecopd.com).39 The instrument consists of ques-
tionnaire items and information from activity monitors,
and has been developed to capture the patient’s experi-
ence of physical activity in two domains: amount of activ-
ity and difficulties with physical activity.
OBJECTIVES
The first objective of the PHYSACTO trial is to confirm
that long-acting muscarinic antagonist (LAMA) therapy and
LAMA/long-acting β2-agonist (LABA) combined therapy,
alone or with exercise training, improve exercise endur-
ance capacity.
The second objective is to evaluate the extent to
which pharmacotherapy alone and in combination with
exercise training can enhance the effects of a behaviour-
change intervention that aims to enhance physical
activity levels. The amount of physical activity is
Table 1 Changes in step count in double-blind studies investigating the effect of pharmacotherapy on physical activity
Group Intervention
Activity
sensor Study design
Duration,
weeks
Baseline
steps
per day
Difference from
placebo in step count,
steps per day
Beeh et al27 Aclidinium SenseWear Crossover 3 7030 459 (7%)
Watz et al28 Indacaterol SenseWear Crossover 3 6618* 722 (11%)
Troosters et al29 Tiotropium SenseWear Parallel group 24 6400 400 (6%)
O’Donnell et al13 Indacaterol SenseWear Crossover 3 46.2 min*† 1.9 min†‡ (4%)
*Data represent the placebo group to give a general idea of physical activity in the study population because baseline data are not available.
†Data presented in physical activity time in min/day.
‡Difference from placebo.
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measured in this trial using validated triaxial acceler-
ometers. In addition, patient-reported physical activity is
assessed as both the perceived amount of activity and
the perceived difficulty of physical activity. Hence, this is
the first trial to explore whether increasing exercise cap-
acity using non-pharmacological and pharmacological
means, in combination with behaviour change, can also
increase the amount of physical activity performed by
patients with COPD.
The trial also explores how patient characteristics and
other factors such as motivation and self-efficacy influ-
ence improvements in physical activity. An additional
objective of the trial is to further validate the PROactive
instrument by testing its sensitivity to interventions in a
randomised clinical trial.
METHODS
Study design
PHYSACTO is a randomised, partially double-blinded,
placebo-controlled, parallel-group trial (NCT02085161)
being conducted at 34 sites in Australia, New Zealand,
the USA, Canada and Europe consisting of 17 academic
institutes, 15 secondary care and 5 primary care centres.
A full list of sites can be obtained at https://clinical-
trials.gov. Patients are randomised in equal ratio to four
groups: placebo, tiotropium 5 µg once daily, tiotropium
+olodaterol 5/5 µg once daily, and tiotropium+oloda-
terol 5/5 µg once daily with exercise training; all
groups will receive 12 weeks of a behaviour-change self-
management programme (figure 1). Medications (active
treatment as well as placebo) are administered using the
Respimat inhaler (Boehringer Ingelheim, Ingelheim am
Rhein, Germany) for 12 weeks and exercise training is
provided for the first 8 weeks of treatment. Patients are
permitted to continue with inhaled corticosteroids but
not LAMAs, LABAs or short-acting muscarinic antago-
nists during the trial, and all are provided with open-
label salbutamol for rescue medication use throughout
the trial. Acute exacerbations can be treated as medic-
ally necessary. This is similar to the approach taken for
other LAMA/LABA development programmes, such as
umeclidinium+vilanterol, which have included several
placebo-controlled studies of 26–52 week duration,40 41
and this is in accordance with statements from the Food
and Drug Administration.42
Inclusion/exclusion criteria
Patients with COPD are included if they have post-
bronchodilator forced expiratory volume in 1 s (FEV1)
≥30% and <80% of predicted normal (Global initiative
for chronic Obstructive Lung Disease 2–3) and did not
experience acute exacerbations in the month prior to
the study, postbronchodilator FEV1/forced vital capacity
<70%, are aged ≥40 years and ≤75 years, and have a
smoking history of >10 pack-years. Patients are excluded
if they have a significant disease other than COPD, a
history of asthma, clinically relevant abnormal baseline
haematology, blood chemistry or urinalysis, or conditions
excluding them from exercise.
Willingness to increase physical activity is not an inclu-
sion criterion but patients have to be willing to take part
in the 8-week exercise training programme (1 in 4 chance
of being randomised to the treatment arm that includes
exercise training) and take part in the behaviour-change
self-management programme.
Behaviour change and exercise training
All patients participate in a 12-week behaviour-change
self-management programme adapted from the ‘Living
Well with COPD’ programme,43 which consists of a self-
management educational programme, support from a
Site Case Manager (SCM) and evaluation using standar-
dised questionnaires to monitor patients’ motivation,
confidence and movement through stages of change.
This is described in detail in Bourbeau et al.35 Patients
also receive a step-counter (OMRON HJ-321) to track
their physical activity in real time towards achievement
of their step-counter goals.
To ensure consistency across sites, a global training
team provides face-to-face training to SCMs from each site
Figure 1 PHYSACTO trial design. *Eight weeks only. AM, activity monitoring, 1 week; BM, behaviour modification at weeks 1,
2, 5, 8, 11 and 15.
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and ensures that the behaviour-change self-management
programme is implemented in a standardised fashion, as
described in detail in Bourbeau et al.35 SCMs also receive
a comprehensive reference guide, and sessions are audio-
taped and sent to a Country Case Manager for centralised
review to ensure quality control and consistency of
sessions.
Exercise training is provided only to patients in one
of the tiotropium+olodaterol 5/5 µg groups and con-
sists of 8 weeks of high-intensity whole-body exercise
training, as well as lower limb resistance training
according to international standards.21 44 It is con-
ducted three times per week in an outpatient rehabili-
tation facility and training logs are kept. Training
intensity is high, and is increased gradually based on
symptom scores for fatigue and dyspnoea. A global
trainer is responsible for ensuring that exercise train-
ing and testing are carried out in a consistent way
across sites.
End points
The primary end point is endurance time during an
endurance shuttle walk test (ESWT)45 to symptom
limitation after 8 weeks of therapy (to reflect the 8-week
duration of the exercise training programme). ESWT is
performed at 85% of maximum oxygen consumption
(VO2 peak) as predicted from an incremental shuttle
walk test conducted at visit 1. A practice ESWT will be
provided during the screening period prior to a baseline
ESWT conducted at a walk speed corresponding to 85%
of VO2 peak. Both 8-week and 12-week ESWT will be
done 2 h (+/−15 min) after inhalation of the study
medication. Table 2 shows the secondary, safety and
exploratory end points.
In order to gain an accurate, objective assessment of
patient physical activity levels, walking intensity, walking
time and number of steps are measured in all patients
using an activity monitor.3 An activity monitor (MoveMonitor
Dynaport, McRoberts, The Hague, the Netherlands) is
worn by patients while they are awake every day for 1 week
at three points in the trial: 1 week during the screening
period; the week prior to the week 9 visit; and the week
prior to the week 12 visit. Patients complete the FPI-SF
questionnaire at clinic visits during screening and at weeks
9 and 12. They also complete the daily PROactive ques-
tionnaire on a personal digital assistant on the days they
Table 2 Trial end points and safety assessments
End point Time
Primary end point Endurance time during ESWT to symptom limitation at 85% of
VO2 peak
Week 8
Secondary end point Average daily walking time measured by activity monitor Week prior to week 12 visit
Secondary end point Average daily walking intensity measured by activity monitor Week prior to week 12 visit
Secondary end point Perceived ease/difficulty with daily activities assessed by FPI-SF Week 12
Secondary end point Endurance time during ESWT to symptom limitation at 85% of
VO2 peak
Week 12
Secondary end point 1 h postdose FEV1 Week 8
Secondary end point 1 h postdose forced vital capacity Week 8
Secondary end point Resting inspiratory capacity measured at 1.5 h postdose Week 8
Further efficacy end point PROactive daily difficulties domain and amount domain scores Week 12/weeks 8, 12
Further efficacy end point Distance measured during 6MWT Weeks 8, 12
Further efficacy end point Intensity of breathing discomfort during 6MWT: pre-exercise,
during exercise and at end-exercise
Weeks 8, 12
Further efficacy end point Intensity of breathing discomfort during ESWT: pre-exercise,
during exercise and at end-exercise
Weeks 8, 12
Further efficacy end point Average number of steps per day measured by the activity
monitor
Week preceding week 9 visit,
week preceding week 12 visit
Further efficacy end point Health status measured by SGRQ Weeks 9, 12
Safety assessments Heart rate and blood pressure in conjunction with spirometry Weeks 1, 8, 12
Safety assessments Heart rate, oxygen saturation and blood pressure in conjunction
with exercise testing
Weeks 8, 12
Safety assessments All adverse events (including physical examination) until end of
study
Throughout
Other outcomes A multivariate regression analysis of the following factors that may
affect activity: motivation, self-efficacy, cognitive function,
depression, anxiety, baseline level of activity, 6MWT distance,
BMI, sex, age, waist circumference, rescue medication use, and
external and internal barriers (eg, environmental/seasonal, social,
economic)
6MWT, 6 min walk test; BMI, body mass index; ESWT, endurance shuttle walk test; FEV1, forced expiratory volume in 1 s; FPI-SF, Functional
Performance Inventory—Short Form; SGRQ, St George’s Respiratory Questionnaire; VO2 peak, predicted maximum oxygen consumption.
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wear the activity monitor. Pulmonary function testing will
be conducted prior to ESWT according to the American
Thoracic Society/European Respiratory Society guide-
lines46 at screening to determine eligibility, prior to ran-
domisation to determine baseline values, and at clinic visits
on the first day of treatment and after 8 and 12 weeks of
treatment.
Safety
Safety assessments include heart rate and blood pressure
in conjunction with spirometry, and heart rate, blood
pressure and oxygen saturation in conjunction with exer-
cise testing. Physical examinations are performed and
adverse events including exacerbations are monitored
carefully throughout the trial.
Randomisation
Randomisation is performed using a pseudorandom
number generator and block randomisation is used to
achieve balanced allocation. Patients are assigned to
treatment arms using a web-based and telephone-based
response system, and provided with numbered medica-
tion boxes. A double-blind design is used for the groups
receiving placebo+behaviour modification, tiotropium
monotherapy+behaviour modification, and tiotropium
+olodaterol+behaviour modification. It is not possible
to blind the participants or staff against the group receiv-
ing tiotropium+olodaterol+exercise training+behaviour
modification. This is because placebo combined with
exercise training is not in accordance with current
recommendations.
Sample size
Using an estimate of SD for a log10-transformed endur-
ance time of 0.213 s, a sample size of 75 patients per
treatment group will provide a power of 80–90% to
detect an improvement of 25–30% in endurance time
between tiotropium+olodaterol 5/5 μg versus placebo
from ESWT. No sample size calculation was performed
for activity variables.
Statistical analysis
The primary end point of endurance time during
ESWT will be log10-transformed to correct for skewness
and an analysis of covariance model, including treat-
ment as a fixed categorical end point and log10-baseline
endurance time as a continuous covariate, will be used.
A similar analysis of covariance model will be used for
the secondary end points. The influence of a number
of moderating variables measured at baseline (motiv-
ation, self-efficacy, cognitive function, depression,
anxiety, baseline level of physical activity, 6 min walk test
distance, body mass index, sex, age, rescue medication
use, and external and internal barriers (eg, environ-
mental/seasonal factors and social and economic
factors)) on increase in the amount of physical activity
and perceived difficulties during physical activity will
also be explored.
Data dissemination
The studies are to be carried out in accordance with
the principles of the Declaration of Helsinki and the
International Conference on Harmonisation Harmonised
Tripartite Guideline for Good Clinical Practice, and
written informed consent will be obtained from each
patient.
DISCUSSION
The PHYSACTO trial is being performed to investigate
how pharmacological interventions in combination with
exercise training can improve exercise capacity. The
study will also investigate to what extent pharmacother-
apy, alone and combined with exercise training, is an
enabler for effective physical activity behaviour change
induced by a self-management programme aiming to
enhance physical activity. To allow investigation of these
questions, multiple interventions are included in the
trial, where the addition of each intervention (the add-
ition of a bronchodilator to placebo, then a second
bronchodilator, etc) is expected to provide an incremen-
tal improvement in exercise capacity and, possibly with
the aid of a behaviour-change programme, an incremen-
tal improvement in physical activity. This will also allow
evaluation of the responsiveness of the instruments
being used to measure physical activity, in particular the
PROactive tool.
In order to evaluate effect size, it was necessary to
include a placebo arm; this also allows the impact of
pharmacotherapy on top of the behaviour intervention
to be determined. A placebo arm was considered accept-
able given that the population has moderate-to-severe
COPD (patients with very severe COPD are not eligible),
the trial duration is 3 months and patients are seen regu-
larly (as part of the behaviour-change programme).
Patients also continue with inhaled corticosteroid therapy
(if taken at baseline), are provided with rescue medica-
tion and withdrawal is considered if there is significant
clinical deterioration (ie, repeated exacerbations or clin-
ical deterioration requiring maintenance therapy not
allowed as per protocol).
It is becoming increasingly clear that COPD disease
management needs to transition from an acute-care
model to a patient-centred, integrated, chronic care
model,47 where different types of intervention are com-
bined to serve individual patient needs. It is expected
that improvements in exercise capacity in this trial will
be directly caused by bronchodilators and exercise train-
ing. A behaviour-change programme was included to
support the translation of increased exercise capacity to
increased physical activity. By providing a combination
of optimal pharmacotherapy and interventions directed
at improving the next limiting factor (ie, skeletal
muscle) and encouraging effective behaviour change,
this trial provides a view on modern integrated COPD
management. Rolling out such a complex intervention
does not come without challenges.
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Exercise training and a behaviour-change programme
in a large multinational study must be standardised and
conducted according to guidelines. This can be particu-
larly challenging in different cultures with varying
health beliefs and communication styles and previous
rehabilitation experience. The purpose of the global
trainer for the exercise training and testing, as well as
that of the global training team for the behaviour-
change programme, is to optimise consistency across
sites. This is described in more detail in another
manuscript.35
Use of the ESWT, activity monitors and patient-
reported outcomes provides the opportunity to first
confirm that the interventions being tested increase
exercise capacity in this trial, and to then identify
whether improvements in exercise capacity are trans-
lated into increased physical activity. The ESWT was
selected as the measure of exercise capacity rather than
constant work-rate cycle ergometry because it is consid-
ered to be more representative of the activities that
patients perform in everyday life, requires less equip-
ment and has adequate measurement properties.45
In this study, exercise training is provided for 8 weeks
while all other interventions are provided for 12 weeks.
Physical activity is measured at 12 weeks to avoid exercise
training confounding the measurement of physical activ-
ity, and also to ensure that there is sufficient time for
patients to resume ‘normal’, and hopefully improved,
activity patterns after exercise training has ended.
Exercise capacity is measured at 8 weeks, at the end of
the exercise training programme. Eight weeks have been
shown to be long enough to increase exercise capacity
with exercise training, bronchodilator therapy and their
combinations.11 12 16 19
Exercise programmes alone may or may not change
individual patient activity levels. Between exercise cap-
acity and physical activity lie a host of moderating vari-
ables that influence a patient’s choice to perform
physical activity.48 49 Since the choice to utilise increased
exercise capacity will vary between individuals, one
might expect the direct statistical relationship between
physical training programmes and physical activity levels
in a clinical trial population to be weak, and the indir-
ect, moderating effects to be stronger.
Therefore, it is important to acknowledge the influ-
ence of physiological, genetic, psychosocial and envir-
onmental factors on a patient’s ability, motivation and
confidence to increase physical activity.48 50 51 The
interactions between patient characteristics (such as
baseline activity level and exercise capacity, anxiety and
age) and physical activity levels are not fully under-
stood,7 and longitudinal interventional studies allowing
for a more direct interpretation of cause and effect are
lacking. It is also known that external factors such as
climate, altitude and season affect physical activity
levels.3 52 The PHYSACTO trial will explore the extent
to which a number of postulated characteristics influ-
ence the increase in amount of physical activity and
perceived difficulties with physical activity demonstrated
in this trial.
There are potential limitations of the study. It is only
partially double-blinded, as it is not possible to blind the
group receiving exercise training; interpretation of the
data from this group will need to take into account the
potential biases associated with the knowledge of treat-
ment group. We did not include a placebo group
without the behaviour-change programme or a run-in
period with the behaviour-change programme and
standard pharmacotherapy in the study design, so the
effects of the behaviour-change self-management pro-
gramme alone cannot be assessed in the present study.
Rather, this study is designed to test whether the add-
ition of more optimal pharmacotherapy (tiotropium or
tiotropium+olodaterol) alone or in combination with
exercise training can enhance the effects of the behav-
iour-change programme. Depending on the results of
this study, further research will most likely be warranted
to address the best approach to support behaviour
change.
Overall, it is hoped that this study will increase our
understanding of how exercise capacity can be increased
in patients with COPD and how this improvement can
be translated into increased physical activity levels. The
trial also prepares the field for comprehensive COPD
patient management, including complementary pharma-
cological and non-pharmacological treatments.
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